Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EPS (Weighted Average and Diluted) (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.15 as the latest value for Q3 2024.

  • For Q3 2024, EPS (Weighted Average and Diluted) fell 7.14% year-over-year to -$0.15; the TTM value through Sep 2024 reached -$0.49, up 22.22%, while the annual FY2024 figure was -$0.59, 1.72% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.15 in Q3 2024 for Crescent Biopharma, up from -$0.16 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.04 in Q1 2024 and bottomed at -$0.34 in Q4 2020.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.21, with a median of -$0.18 recorded in 2022.
  • On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 76.47% in 2024 and fell as far as 23.08% in 2024.
  • Crescent Biopharma's EPS (Weighted Average and Diluted) stood at -$0.34 in 2020, then rose by 3.05% to -$0.33 in 2021, then surged by 42.42% to -$0.19 in 2022, then rose by 26.32% to -$0.14 in 2023, then fell by 7.14% to -$0.15 in 2024.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.15, -$0.16, and -$0.04 for Q3 2024, Q2 2024, and Q1 2024 respectively.